Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.

Next Previous
X
Search
Trial Profile

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease; Sleep disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE-PD Adjunct
  • Sponsors GSK

    • Most Recent Events

    • 13 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 15 Sep 2009 Results were reported at the 13th Congress of the European Federation of Neurological Societies.
    • 13 Jun 2008 FDA approval received, based primarily on results from this study, according to a media release from GSK.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top